AlphAIAlphAI — Financial news for AI agents
247wallst.comSEP 172 min read$TEM

Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook

Tempus AI (TEM) shares surged 29.98% this week after Morgan Stanley highlighted new reimbursement-driven revenue growth. CEO Eric Lefkofsky estimated xT pricing could add $80M-$100M in 2025, and xF approval $250M-$300M annually. Q2 revenue was $382.49M, up 21.6% YoY, with full-year guidance raised to $1.595B-$1.605B. Analysts revised FY2027 EPS estimates positively, with a consensus revenue estimate of $1.97B.

Original reporting
247wallst.com
Published Sep 17, 2026, 4:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 5:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook — source image
Source · 247wallst.com
Decision brief

The 30-second read

$TEMBullishMed
01

Why it matters

Morgan Stanley's commentary adds fresh revenue uplift estimates, likely driving further price appreciation.

02

Market read

Analyst upgrade with concrete numbers fuels a near‑term rally in a high‑growth biotech.

03

What to watch

Potential regulatory or payer pushback on reimbursement pricing not addressed.

Relevance 7/10Novelty 7/10Timing: Thursday session

Background

Tempus AI reported Q2 FY2026 results with 21.6% YoY revenue growth and raised full‑year guidance.

Company-level read

Ticker impact

$TEMBullishHigh confidence
Context

Morgan Stanley raised Tempus AI's revenue outlook, citing $80‑$100M from xT and $250‑$300M from xF, prompting a 30% price surge.

Expected impact

Potential continuation of rally if guidance holds; watch for target revisions.

Evidence & confidence

Specific, previously undisclosed revenue numbers and guidance raise provide a clear catalyst.

Market effects

Sector

Positive signal for AI‑driven diagnostics and precision‑medicine sector.

Regional

U.S. biotech and health‑tech stocks may see modest gains.

Global

Highlights growing reimbursement support for AI diagnostics worldwide.

Counterpoint

What could challenge this read

High beta and ongoing GAAP losses could limit upside; valuation may still be stretched.

Key entities

  • Company
    Tempus AI

    AI‑powered diagnostics firm (NASDAQ:TEM).

  • Analyst
    Morgan Stanley

    Equity research firm providing the revenue outlook boost.

Read at source← All news

Related articles

SEP 17
$TEMMedAI 8/10

TEM Stock Jumps As Tempus AI Joins Profitable AI Health Elite

Tempus AI Inc. (NASDAQ: TEM) shares rose 14.38% on September 17, 2026, driven by strong Q2 2026 results. Revenue grew 22% YoY to $382.5M, with net income and EBITDA turning positive at $5.6M and $45M, respectively. Gross margin is 73.5%. The company plans to acquire Personalis, funded by $816M in cash and investments, despite $1.36B in long-term debt. TEM's stock has surged from $62 to $80, attracting momentum traders.

timothysykes.com3 min
SEP 15
$TEMHighAI 8/10

Tempus AI (TEM) Jumps As Upgrade, Acquisition Fuel Bullish Momentum

Tempus AI Inc. (TEM) shares rose 6.62% after Piper Sandler upgraded it to Overweight with a $76 price target. The company reported Q2 2026 revenue of $382.5M, up 22% YoY, and turned profitable. TEM is acquiring Personalis for $1.5B to expand its tumor-sequencing platform. The stock trades near $66.33, with strong cash position and improving margins.

stockstotrade.com3 min
SEP 5
$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

finance.biggo.com4 min
SEP 2
$TEMHighAI 9/10

Tempus AI gets FDA clearance for pulmonary hypertension AI tool

Tempus AI (NASDAQ: TEM) received FDA clearance for its AI tool, Tempus ECG-PH, which analyzes ECGs for pulmonary hypertension. This is the third FDA-cleared device in its cardiovascular portfolio. Tempus shares rose 5.09% to $70.04, driven by positive Phase 3 trial results from Moderna and Merck, which validate the $1.5 billion acquisition of Personalis.

scanx.trade3 min